Decoding the role of miRNAs in multiple myeloma pathogenesis: a focus on signaling pathways
AM Yehia, EGE Elsakka, AI Abulsoud… - … -Research and Practice, 2023 - Elsevier
Multiple myeloma (MM) is a cancer of plasma cells that has been extensively studied in
recent years, with researchers increasingly focusing on the role of microRNAs (miRNAs) in …
recent years, with researchers increasingly focusing on the role of microRNAs (miRNAs) in …
[HTML][HTML] Mir-34: a new weapon against cancer?
The microRNA (miRNA)-34a is a key regulator of tumor suppression. It controls the
expression of a plethora of target proteins involved in cell cycle, differentiation and …
expression of a plethora of target proteins involved in cell cycle, differentiation and …
[HTML][HTML] Research advances on matrine
XY Sun, LY Jia, Z Rong, X Zhou, LQ Cao, AH Li… - Frontiers in …, 2022 - frontiersin.org
Matrine is an alkaloid extracted from traditional Chinese herbs including Sophora
flavescentis, Sophora alopecuroides, Sophora root, etc. It has the dual advantages of …
flavescentis, Sophora alopecuroides, Sophora root, etc. It has the dual advantages of …
[HTML][HTML] miRNAs and lncRNAs as novel therapeutic targets to improve cancer immunotherapy
Simple Summary Cancer onset and progression are promoted by high deregulation of the
immune system. Recently, major advances in molecular and clinical cancer immunology …
immune system. Recently, major advances in molecular and clinical cancer immunology …
[HTML][HTML] Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation
Bone disease is the most frequent complication in multiple myeloma (MM) resulting in
osteolytic lesions, bone pain, hypercalcemia and renal failure. In MM bone disease the …
osteolytic lesions, bone pain, hypercalcemia and renal failure. In MM bone disease the …
[HTML][HTML] Roles of miRNA dysregulation in the pathogenesis of multiple myeloma
D Chen, X Yang, M Liu, Z Zhang, E Xing - Cancer gene therapy, 2021 - nature.com
Multiple myeloma (MM) is a malignant disease of plasma cells with complex pathology,
causing significant morbidity due to its end-organ destruction. The outcomes of patients with …
causing significant morbidity due to its end-organ destruction. The outcomes of patients with …
[HTML][HTML] Circulating cell-free miRNAs as biomarker for triple-negative breast cancer
VY Shin, JM Siu, I Cheuk, EKO Ng, A Kwong - British journal of cancer, 2015 - nature.com
Background: Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancer
in women globally. This subtype often has early and high recurrence rates resulting in poor …
in women globally. This subtype often has early and high recurrence rates resulting in poor …
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells
Purpose: The onset of drug resistance is a major cause of treatment failure in multiple
myeloma. Although increasing evidence is defining the role of miRNAs in mediating drug …
myeloma. Although increasing evidence is defining the role of miRNAs in mediating drug …
[HTML][HTML] miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
A wealth of studies has highlighted the biological complexity of hematologic malignancies
and the role of dysregulated signal transduction pathways. Along with the crucial role of …
and the role of dysregulated signal transduction pathways. Along with the crucial role of …
[HTML][HTML] Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
E Morelli, E Leone, ME Cantafio, MT Di Martino… - Leukemia, 2015 - nature.com
Abstract Interferon regulatory factor 4 (IRF4) is an attractive therapeutic target in multiple
myeloma (MM). We here report that expression of IRF4 mRNA inversely correlates with …
myeloma (MM). We here report that expression of IRF4 mRNA inversely correlates with …